Quipt Home Medical Corp. (QIPT Q1 FY2025 earnings call

• Consistent demand across all major product categories in fiscal Q1 2025.
• Adjusted EBITDA margin improved sequentially to 22.8% due to operational optimizations.
• Sleep business: GLP-1 medications have no impact on demand; referral activity and replacement supply volumes are solid. Recent data shows GLP-1 improves OSA treatment adherence.
• Regulatory environment for sleep business is stable. The AASM emphasizes positive airway pressure therapy for OSA.
• Focus on organic growth, operational efficiency, and expanding market presence through strategic initiatives.

Respiratory care comprises approximately 77% of the product mix. For the first quarter of fiscal '25, revenue was $61.4 million, with adjusted EBITDA of $14 million and a margin of 22.8%. There was a 3% increase in unique setups and deliveries to 221,000 compared to fiscal Q1 2024. Respiratory resupply setups and deliveries grew 1% year-over-year to $124,000. The customer base grew 1% to 157,000 unique patients as of December 31, 2024.

• Expect steady margin expansion throughout fiscal '25 due to operational discipline.
• Goal to return to historical organic growth rates through initiatives like improving catchment rates and sales training.
• Plan to continue optimizing cost structure and explore strategic growth opportunities, including inorganic and organic.

• Discontinuation of Medicare 75-25 blended rate negatively impacted revenue.
• Withdrawal of Medicare Advantage members in certain regions.
• Disposal supply contract termination, estimated $2.5 million headwind in 2025.
• Need to replace Philips Respironics ventilators, which may impact margins in the near term.

Q: Provide background on disposable supply contract termination and remaining headwind in fiscal '25?

A: It was an incontinence supply contract terminated in November, expected $2.5 million headwind in 2025, more heavily weighted in first quarter.

Q: Thoughts on capitated contracts shifting and remaining headwinds?

A: Humana impact most in first couple quarters of 2025, PPO contracts stabilized.

Q: Margins and cost efficiencies progression?

A: Margins stabilized, goal is organic growth, with potential to adjust cost structure if needed, aiming for margin improvement.

Q: Resupply business traction and plans to drive growth?

A: Working on improving catchment rates, sleep compliance, and following patients longer to increase resupply patients.

Q: Medicare reimbursement impact from government efficiency?

A: No immediate known impact, but monitoring regulatory changes.

Q: Organic growth expectations and progress?

A: Working on multiple levers like new therapy utilization, sales training, catchment rate improvement, aiming for historical organic growth rates.

Q: Health expense commentary?

A: Self-insured health costs stabilized after initial ramp-up, targeting nominal annual increases.

Q: Capital deployment commentary?

A: Evaluating strategic growth opportunities, including inorganic and organic, actively engaged in looking at opportunities.